Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infigratinib in Advanced GC/GEJ or Solid Tumors with FGFR Alterations
NCT05019794Phase 2Unknown
- Sponsor
- LianBio
- Start
- May 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of infigratinib in gastric cancer (GC), gastroesophageal junction adenocarcinoma and solid tumor (2 arms), sponsored by LianBio. Primary endpoint: Objective Response Rate at 12 months. Status: unknown.
02
Drugs
infigratinib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinomasolid tumor
Beyond the preview
Go deeper on NCT05019794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05019794.